Posts by Sandra Ansanay-Alex
Green Lab Symposium
The Green Lab Symposium is taking place on 11 June 2026 at Life Science Centre PULSE – Cheseaux-sur-Lausanne Green Lab is an initiative of the association ‘Green Building Switzerland’. This non-profit organisation acts as a competent catalyst to strengthen the competitiveness of Swiss cutting-edge research through innovative and sustainable laboratories. The Green Lab Symposium is…
Read MoreSeprify Raised CHF 12.25 million in Series A Funding
Seprify, a spin-off from the University of Fribourg and the University of Cambridge, now based at the Marly Innovation Centre (MIC), is a bio-materials company developing high-performance cellulose-based ingredients for industrial applications, announced the transition of its cellulose platform from pilot validation into procurement-ready industrial supply. This enables manufacturers to move from trials into repeatable…
Read MoreGiannina Iannotti, from HUG NeuroCentre, Received the BCV 2025 Sustainability Award
Giannina Iannotti, coordinator of the HUG NeuroCentre, received the BCV 2025 Sustainability Award, given to the HEC Lausanne Executive MBA strategic consulting project with the greatest impact in terms of sustainability. An academic project with real-world benefits The Optimising HUG Outpatient Care for Mild and Moderate Traumatic Brain Injury project proposes a sustainable model rooted…
Read MorePolares Medical Raises $50 million in Series C Funding
The funding was supported by DC Global Ventures, Lumination Capital, existing investors and a new strategic investor, to help advance MRace‘s US expansion following strong clinical results. Polares Medical SA (‘Polares’), a Swiss Health Valley clinical-stage structural heart company developing the MRace mitral valve replacement system for mitral valve regurgitation (MR), announced the closing of…
Read MoreTherapy Dogs Bring Comfort to Children with Cancer at CHUV
Two therapy dogs have recently joined the daily life of children hospitalized in the Pediatric Hematology-Oncology Unit at the Children’s Hospital of Lausanne University Hospital (CHUV). This pilot initiative — the first of its kind in Switzerland within a pediatric oncology unit — represents an important step forward in integrating complementary therapies to support the…
Read MoreSwiss MedTech Startup HeroSupport Secures CE Mark for VENUS SHELL™
On International Women’s Day, HeroSupport, a University of Geneva spinoff, announced that its first medical device, VENUS SHELL™, has received CE Mark certification and is now authorised for marketing across the European Union and Switzerland. The CE mark confirms compliance with all applicable EU health, safety, and environmental standards. It enables deployment in hospitals and…
Read MoreNovigenix AI Spin-Out to Accelerate AI-Powered Immune Intelligence
Novigenix SA, a Swiss Health Valley leader in immunotranscriptomic diagnostics, announced the formal spin-out and launch of Novigenix AI, a new precision medicine company dedicated to transforming therapy development through AI-powered immune intelligence. A Strategic Separation to Unlock Two High-Growth Markets The new AI spin-out separates Novigenix’s colorectal cancer (CRC) screening business from its rapidly…
Read MoreHUG Launch a Women’s Cardiovascular Health Center
The Hôpitaux universitaires de Genève (HUG) announce the creation of a new Women’s Cardiovascular Health Center, a dedicated initiative designed to improve the diagnosis, prevention, and treatment of cardiovascular diseases in women. Cardiovascular diseases remain the leading cause of death in Switzerland, accounting for approximately 20,000 deaths each year, according to the Federal Office of…
Read MoreAlithea Genomics Closes CHF 6.9 M Seed Round
The Biopôle-based emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced the closing of its seed financing round with an additional CHF 3 million ($3.9 million), led by Genku Ventures and joined by Novalis Biotech and Zürcher Kantonalbank as well as several private investors. This additional funding brings the total seed round…
Read MoreXsensio SA Raises $7 Million in Oversubscribed Series A Funding
Xsensio SA, a Vaud-based high-tech company pioneering continuous biochemical monitoring in near real time, announced the closing of a Series A funding round with an oversubscription of $7 million. The round was led by San Francisco-based venture capital firm WI Harper, with participation from Privilège Ventures, the European Innovation Council and private investors from the…
Read More